ArticleThe Journal of experimental medicine2019
EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 56 citations in OpenAlex.
- Megakaryocytes in myelofibrosis: mechanisms of fibrotic niche remodeling and therapeutic implications.Biomarker research · 2026Review
- Activated Platelet-Released Heat Shock Protein 90α Triggers Autophagy-Dependent Neutrophil Extracellular Trap Formation and Amplifies Sepsis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- DAMP signaling networks: from receptors to diverse pathophysiological functions.Journal of advanced research · 2026Review
- Thermo-Chemically Modified Silk Scaffolds Reveal Niche-Driven Regulation of Hematopoiesis and Fibrosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Article
- Matrix molecules associated with both regulation of inflammation and pathogenic outcomes associated with the surface of the lens in the eyes of EAU mice.Experimental eye research · 2025Article
- SPP1hi macrophages, NKG7 T cells, CCL5hi fibroblasts, and IgM plasma cells are dominant features of necrobiosis.JCI insight · 2025Article
- Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis.Journal of translational medicine · 2025Article
- A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.Science translational medicine · 2024Article
- Article
- Bone marrow inflammation in haematological malignancies.Nature reviews. Immunology · 2024Review
- Circulating plasma fibronectin affects tissue insulin sensitivity, adipocyte differentiation, and transcriptional landscape of adipose tissue in mice.Physiological reports · 2024Article
- DDX5 inhibits hyaline cartilage fibrosis and degradation in osteoarthritis via alternative splicing and G-quadruplex unwinding.Nature aging · 2024Article
- Deregulation of the p19/CDK4/CDK6 axis in Jak2Leukemia · 2024Article
- Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis.American journal of hematology · 2024Article
- Elevated levels of damage-associated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis.Frontiers in immunology · 2024Article
- Extracellular Matrix-Derived Damage-Associated Molecular Patterns (DAMP): Implications in Systemic Sclerosis and Fibrosis.The Journal of investigative dermatology · 2023Review
- Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.Cancers · 2023Review
- Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3.Blood advances · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 2 countries.
Alessandro MalaraDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Cristian GruppiDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Vittorio AbbonanteDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.ORCID 0000-0001-8066-9895
Daniele CattaneoHematology Division, Istituto di Ricovero e Cura a Carattere Scientific Ca' Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy.
Luigi De MarcoDepartment of Translational Research, National Cancer Center (Istituto di Ricovero e Cura a Carattere Scientific Centro di Riferimento Oncologico), Aviano, Italy.ORCID 0000-0001-9902-8107
Margherita MassaLaboratory of Biochemistry, Biotechnology and Advanced Diagnostics, Istituto di Ricovero e Cura a Carattere Scientific San Matteo Foundation, Pavia, Italy.
Alessandra IurloHematology Division, Istituto di Ricovero e Cura a Carattere Scientific Ca' Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy.
Umberto GianelliDivision of Pathology, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.ORCID 0000-0003-3304-8417
Carlo L BalduiniDepartment of Internal Medicine, Istituto di Ricovero e Cura a Carattere Scientific San Matteo Foundation, Pavia, Italy.
Maria E TiraDepartment of Biology and Biotechnology "Lazzaro Spallanzani," University of Pavia, Pavia, Italy.
Andrès F MuroThe International Center for Genetic Engineering and Biotechnology, Trieste, Italy.ORCID 0000-0002-9628-0494
Anil K ChauhanDepartment of Internal Medicine, University of Iowa, Iowa City, IA.
Vittorio RostiCenter for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, Istituto di Ricovero e Cura a Carattere Scientific Policlinico S. Matteo Foundation, Pavia, Italy.
Giovanni BarosiCenter for the Study of Myelofibrosis, Laboratory of Biochemistry, Biotechnology and Advanced Diagnostics, Istituto di Ricovero e Cura a Carattere Scientific Policlinico S. Matteo Foundation, Pavia, Italy.
Alessandra BalduiniDepartment of Molecular Medicine, University of Pavia, Pavia, Italy alessandra.balduini@tufts.edu.ORCID 0000-0003-3145-1245
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Pavia · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITInternational Centre for Genetic Engineering and Biotechnology · ITScripps Research Institute · USTufts University · USUniversity of Iowa · USUniversity of Milan · IT
Funding
Targeting Pyruvate Kinase M2: A novel strategy to combat thrombo-inflammationR35HL139926 · NHLBI · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR · 2018 to 2024
$5.3MNovel therpeautic interventions to treat ischemic strokeR01NS109910 · NINDS · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR · 2019 to 2023
$1.8MThe role of glycans in thrombopoiesisR01HL134829 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GIANNINI, SILVIA · 2017 to 2019
$1.1MNHLBI NIH HHS R01 HL134829NHLBI NIH HHS R35 HL139926NINDS NIH HHS R01 NS109910
Abstract
The fibronectin EDA isoform (EDA FN) is instrumental in fibrogenesis but, to date, its expression and function in bone marrow (BM) fibrosis have not been explored. We found that mice constitutively expressing the EDA domain (EIIIA
Indexed as
AdultAgedAged, 80 and overAlternative SplicingAnimalsCase-Control StudiesCell DifferentiationFemaleFibronectinsHumansMaleMegakaryocytesMice, Inbred C57BLMice, KnockoutMiddle AgedOsteomyelitisextra domain A fibronectin, humanextra domain A fibronectin, mouseFibronectinsThrombopoietinTlr4 protein, mouseToll-Like Receptor 4
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.